<DOC>
	<DOCNO>NCT01715168</DOCNO>
	<brief_summary>The purpose study find answer follow research question ( ) : 1 . Is study drug equivalent approve drug , Doxil/Caelyx , act way body approve drug ? ATI-0918 believe generic Doxil/Caelyx study try prove . All people participate study receive research study medication ( ATI-0918 ) Doxil/Caelyx addition best supportive care ( treatment symptom ) . The study drug test study work FDA ( government ) approve drug doxorubicin HCl . ATI-0918 generic ( ) formulation doxorubicin HCl deliver ( give patient ) .</brief_summary>
	<brief_title>A Crossover Bioequivalence Study Intravenously Administered ATI0918 DOXIL/CAELYX Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>1 . Have histologically confirm ovarian cancer potentially sensitive DOXIL/CAELYX 2 . Have disease progression recurrence maximum 2 prior chemotherapy , one platinum base . 3 . Be DOXIL/CAELYX treatment naïve 4 . Have normal leave ventricular ejection fraction ( LVEF ) base institutional range . 5 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 6 . Have estimate life expectancy ≥ 3 month 7 . Be &gt; /= 18 &lt; /= 70 year age 8 . Sign write Institutional Review Board ( IRB ) approve informed consent form 9 . Have negative pregnancy test , patient childbearing potential 10 . Have acceptable liver function : Bilirubin &lt; /= upper limit normal ( ULN ) AST ( SGOT ) , ALT ( SGPT ) Alkaline phosphatase &lt; /= 1.5 time upper limit normal 11 . Have acceptable renal function : Serum creatinine within normal limit , OR calculate creatinine clearance &gt; /= 60 mL/min/1.73 m2 patient creatinine level institutional normal . 12 . Have acceptable hematologic status : Neutrophils &gt; /= 1500 cells/mm3 Platelet count &gt; /= 100,000 ( plt/mm3 ) Hemoglobin &gt; /= 9 g/dL 13 . Have acceptable coagulation status : Prothrombin time ( PT ) International Normalized Ratio ( INR ) within 1.5 × ULN Partial thromboplastin time ( PTT ) within 1.5 × ULN 14 . Agree use effective contraceptive method study ( nonsterile patient childbearing potential ) 1 . Have New York Heart Association ( NYHA ) Class III IV cardiac disease , myocardial infarction within past 6 month prior Day 1 , unstable arrhythmia , evidence ischemia electrocardiogram ( ECG ) Cardiac Stress Testing within 14 day prior Day 1 2 . Have receive &gt; 250 mg/m2 doxorubicin equivalent anthracyclines similar compound 3 . Have receive prior treatment DOXIL/CAELYX 4 . Have receive radiotherapy mediastinal area concomitant therapy potentially cardiotoxic agent 5 . Have seizure disorder require anticonvulsant therapy 6 . Have know brain metastasis ( unless previously treat well controlled period &gt; /= 3 month ) 7 . Have severe chronic obstructive pulmonary disease hypoxemia 8 . Have major surgery , diagnostic surgery , within 4 week prior Day 1 9 . Have active , uncontrolled bacterial , viral , fungal , opportunistic infection require systemic therapy 10 . Are pregnant nursing . NOTE : Nonsterile woman childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . 11 . Have receive treatment radiation therapy , surgery , chemotherapy , investigational therapy within one month prior study entry ( 6 week nitrosoureas Mitomycin C ) . 12 . Have receive radiation therapy &gt; 25 % total bone marrow lifetime 13 . Are unwilling unable comply procedure require protocol 14 . Have know infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C 15 . Have serious nonmalignant disease ( e.g. , hydronephrosis , liver failure , significantly impair hepatic function , condition ) could compromise protocol objective opinion investigator and/or sponsor 16 . Are currently receive investigational agent 17 . Have exhibit allergic reaction doxorubicin similar structural compound</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Doxil generic</keyword>
	<keyword>Caelyx generic</keyword>
	<keyword>generic treatment</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>ovary</keyword>
	<keyword>progress</keyword>
	<keyword>recur cancer</keyword>
	<keyword>platinum base therapy</keyword>
</DOC>